Skip to content
Screener

Design Therapeutics, Inc. DSGN Cash & Equivalents

Cash & Equivalents at other companies

ALN
Alnylam PharmaceuticalsALNY
$1.71B+53.2%
Intellia Therapeutics logo
Intellia TherapeuticsNTLA
$106.13M-32.0%
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
$423.31M+80.0%
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
$753.1M+59.5%
CytomX Therapeutics logo
CytomX TherapeuticsCTMX
$17.22M-64.9%
Taysha Gene Therapies, Inc. logo
Taysha Gene Therapies, Inc.TSHA
$276.58M+137%

Other financials

Income statement

See full
Revenue-—
Operating income-$19.7M+3.5%
Net income-$17.6M+0.4%
EPS (diluted)-$0.29+6.5%

Balance sheet

See full
Total debt$2.7M+27.7%
Total equity$218.1M-4.3%
Total assets$230.4M-3.0%

Cash flow

See full
Operating cash flow-$16.4M+2.1%
CapEx--100%
Free cash flow-$16.4M+2.6%

Valuation

See full
Market cap$875.52M+219%
Enterprise value$865.48M+237%

Profitability

See full
Operating margin-3,685.8%—
Net margin-3,663.7%—

Returns & leverage

See full
Return on equity-31.3%+19.5pp
Debt / equity0×0.0×
Current ratio22.3×-6.1×

Where this comes from

Reported directly by Design Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The source filing: Design Therapeutics, Inc.’s 10-Q, filed April 28, 2026.

Filed
Apr 28, 2026, 4:13 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-187063
Line itemMarch 31, 2026December 31, 2025
(unaudited)
Assets
Current assets:
Cash and cash equivalents$12,770$16,856
Investment securities210,053202,989
Prepaid expenses and other current assets4,2263,939
Total current assets227,049223,784
Property and equipment, net824981

Item 1. Financial Statements.

FAQ

What is Design Therapeutics, Inc.'s cash & equivalents?
Design Therapeutics, Inc. (DSGN) reported cash & equivalents of $12.77M in Q1 2026.
How has Design Therapeutics, Inc.'s cash & equivalents changed year-over-year?
Design Therapeutics, Inc.'s cash & equivalents decreased by 6.6% year-over-year, from $13.67M to $12.77M.
What is the long-term trend for Design Therapeutics, Inc.'s cash & equivalents?
Over 5 years (2020 to 2025), Design Therapeutics, Inc.'s cash & equivalents has grown at a 47.9% compound annual growth rate (CAGR), from $2.38M to $16.86M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

Ask your AI about Design Therapeutics, Inc.'s cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude